Reader S C, Davison B, Beardwell C, Ratcliffe J G, Robertson W R
Clin Endocrinol (Oxf). 1986 Oct;25(4):441-51. doi: 10.1111/j.1365-2265.1986.tb01711.x.
Protein-A purified human thyroid stimulating immunoglobulins (TSIg) and thyrotrophin binding inhibiting immunoglobulins (TBIIg) were measured in euthyroid subjects and thyrotoxic patients by bioassay and TSH radioligand receptor assay respectively. Unextracted sera from euthyroid and thyrotoxic subjects inhibited both basal and TSH stimulated iodide uptake in the bioassay, which was based on iodide uptake in porcine thyrocytes. Similar effects were seen with Ig and TSIg extracted from sera using either polyethylene glycol or ammonium sulphate. However IgG and TSIg prepared using Protein-A Sepharose CL-4B from sera of euthyroid subjects had little effect in this system. The majority of Protein-A purified TSIg preparations from sera of thyrotoxic patients stimulated iodide uptake in procine thyrocytes in a dose-dependent manner and most (85%) diluted parallel to both bovine and human TSH. TSIg and TBIIg from 73 patients with thyrotoxicosis were assessed using the bioassay and receptor assay and compared to a control group of 35 euthyroid subjects. The median (and range) values for TSIg and TBIIg in the euthyroid group were 4.35 (0.8 to 7.5, % stimulation over control) and 2.7 (-9.3 to 8.6, TBII index) for the bioassay and radioreceptor assay respectively. A value of greater than 10.0 in both assays was taken as a positive result. Of the thyrotoxic patients 61 out of 73 were positive in the bioassay (83.6%) compared to 60 in the radioreceptor assay (82.2%). There was a positive correlation between the two assays (r = 0.821, P less than 0.001). Of the 73 thyrotoxic patients 40 were untreated, 18 had received carbimazole and 15 had been previously treated with iodine-131. TSIg levels in the untreated thyrotoxics were similar to those in either group of treated patients. However they were higher (P less than 0.05) in the iodine-131 group than in the patients treated with carbimazole. Similar results were obtained for TBIIg. The coupling of a specific extraction method for human serum IgG with a bioassay for TSIg has demonstrated a high prevalence of these immunoglobulins in patients with thyrotoxicosis. The agreement between this assay and a radioreceptor assay was good, indicating that TSH displacing and thyroid stimulating activities of these immunoglobulins are closely related.
分别通过生物测定法和促甲状腺激素放射性配体受体测定法,对甲状腺功能正常的受试者和甲状腺毒症患者体内经蛋白A纯化的人促甲状腺免疫球蛋白(TSIg)和促甲状腺素结合抑制免疫球蛋白(TBIIg)进行了检测。在基于猪甲状腺细胞碘摄取的生物测定中,甲状腺功能正常和甲状腺毒症受试者的未提取血清均抑制基础碘摄取和促甲状腺激素刺激的碘摄取。使用聚乙二醇或硫酸铵从血清中提取的免疫球蛋白(Ig)和TSIg也观察到类似效果。然而,用蛋白A琼脂糖凝胶CL-4B从甲状腺功能正常受试者血清中制备的IgG和TSIg在该系统中作用甚微。从甲状腺毒症患者血清中经蛋白A纯化得到的大多数TSIg制剂,能以剂量依赖方式刺激猪甲状腺细胞摄取碘,且大多数(85%)与牛和人促甲状腺激素呈平行稀释。采用生物测定法和受体测定法对73例甲状腺毒症患者的TSIg和TBIIg进行了评估,并与35例甲状腺功能正常的受试者组成的对照组进行比较。甲状腺功能正常组TSIg和TBIIg在生物测定法和放射受体测定法中的中位数(及范围)值分别为4.35(0.8至7.5,相对于对照组的刺激百分比)和2.7(-9.3至8.6,TBII指数)。两种测定中数值大于10.0被视为阳性结果。在73例甲状腺毒症患者中,生物测定法有61例呈阳性(83.6%),放射受体测定法有60例呈阳性(82.2%)。两种测定之间存在正相关(r = 0.821,P<0.001)。73例甲状腺毒症患者中,40例未接受治疗,18例接受过卡比马唑治疗,15例曾接受过碘-131治疗。未治疗的甲状腺毒症患者的TSIg水平与两组接受治疗患者的水平相似。然而,碘-131治疗组的TSIg水平高于卡比马唑治疗组(P<0.05)。TBIIg也得到类似结果。将人血清IgG的特异性提取方法与TSIg生物测定法相结合,已证明这些免疫球蛋白在甲状腺毒症患者中具有较高的患病率。该测定法与放射受体测定法之间的一致性良好,表明这些免疫球蛋白的促甲状腺激素置换活性和甲状腺刺激活性密切相关。